SPPI — Spectrum Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- $211.40m
- $184.11m
- $10.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.87 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.47 | ||
| Price to Tang. Book | 7.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -92.31% | ||
| Return on Equity | -165.02% | ||
| Operating Margin | -246.82% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 10.11 | 73.38 | 126 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Spectrum Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
Directors
- William Ashton NEC (70)
- Thomas Riga PRE (46)
- Kurt Gustafson CFO (53)
- Francois Lebel EVP (69)
- Keith Mcgahan SVP (45)
- Nora Brennan IND (52)
- Seth Fischer IND (65)
- Jeffrey Vacirca IND (52)
- Dolatrai Vyas IND (77)
- Bernice Welles IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- November 18th, 2002
- Public Since
- September 26th, 1996
- No. of Shareholders
- 157
- No. of Employees
- 86
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 205,245,727
- Address
- 11500 S Eastern Ave Ste 240, HENDERSON, 89052-5576
- Web
- https://www.sppirx.com/
- Phone
- +1 7028356300
- Auditors
- RSM US LLP
Upcoming Events for SPPI
Q2 2023 Spectrum Pharmaceuticals Inc Earnings Release
Q3 2023 Spectrum Pharmaceuticals Inc Earnings Release
Similar to SPPI
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Spectrum Pharmaceuticals share price?
As of Today at 01:21 UTC, shares in Spectrum Pharmaceuticals are trading at $0.98. This share price information is delayed by 15 minutes.
How has the Spectrum Pharmaceuticals share price performed this year?
Shares in Spectrum Pharmaceuticals last closed at $0.98 and the price had moved by +19.19% over the past 365 days. In terms of relative price strength the Spectrum Pharmaceuticals share price has outperformed the S&P500 Index by +2.32% over the past year.
What are the analyst and broker recommendations for Spectrum Pharmaceuticals?
The overall consensus recommendation for Spectrum Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Spectrum Pharmaceuticals dividend yield?
Spectrum Pharmaceuticals does not currently pay a dividend.
Does Spectrum Pharmaceuticals pay a dividend?
Spectrum Pharmaceuticals does not currently pay a dividend.
When does Spectrum Pharmaceuticals next pay dividends?
Spectrum Pharmaceuticals does not currently pay a dividend.
How do I buy Spectrum Pharmaceuticals shares?
To buy shares in Spectrum Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Spectrum Pharmaceuticals?
As of the previous close price of $0.98, shares in Spectrum Pharmaceuticals had a market capitalisation of $200.75m.
Where are Spectrum Pharmaceuticals shares listed?
Here are the trading details for Spectrum Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SPPI
What kind of share is Spectrum Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Spectrum Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Spectrum Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Spectrum Pharmaceuticals is $1.26. That is 28.82% above the last closing price of $0.98.
Analysts covering Spectrum Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.05 for the next financial year.
What is the trend in the Spectrum Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Spectrum Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +48.53%.
As of the last closing price of $0.98, shares in Spectrum Pharmaceuticals were trading +32.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Spectrum Pharmaceuticals PE Ratio?
The Spectrum Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 18.87. The shares last closed at $0.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' management team is headed by:
- William Ashton - NEC
- Thomas Riga - PRE
- Kurt Gustafson - CFO
- Francois Lebel - EVP
- Keith Mcgahan - SVP
- Nora Brennan - IND
- Seth Fischer - IND
- Jeffrey Vacirca - IND
- Dolatrai Vyas - IND
- Bernice Welles - IND